After J.P. Morgan and UBS gave Roche Holding AG (Other OTC: RHHVF) a Buy rating last month, the company received another Buy, this time from Goldman Sachs. Analyst Keyur Parekh maintained a Buy rating on Roche Holding AG today and set a price target of CHF384.00. The company’s shares closed last Monday at $360.04.
Parekh has an average return of 16.0% when recommending Roche Holding AG.
According to TipRanks.com, Parekh is ranked #3261 out of 6927 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roche Holding AG with a $423.01 average price target, implying a 17.5% upside from current levels. In a report issued on September 2, J.P. Morgan also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $399.00 and a one-year low of $274.15. Currently, Roche Holding AG has an average volume of 3,777.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
